Health inspection·March 16, 2023

F 0755 Level of Harm - Minimal harm or potential for actual harm Provide pharmaceutical services to meet the needs of each resident and employ or obtain the services of a licensed pharmacist. Based on interviews, record reviews and policy reviews, the facility failed to ensure accurate accounting of controlled substances for 3 of 7 residents sampled (Residents #20, #57, and #155). Residents Affected - Some The findings include: A review was conducted of the controlled drug declining inventory sheets and the electronic medication administration record. The following discrepancies were identified: Resident # 155 Diazepam (anxiety) 2 mg (milligrams) - 6 tablets were marked as on hand on 3/9/23 on the Controlled Drug Declining Inventory Sheet. Further review of the sheet revealed that one tablet of diazepam was administered on 3/9/23 at 8:30 AM, 3:00 PM, and 9:00 PM, 3/10/23 at 3:00 AM, 1:30 PM, and 11:00 PM, equaling 6 tablets with zero tablets remaining. However, review of the Medication Administration Record (MAR) for March 2023 revealed the medication was documented as administered 4 times (3/9/23 at 8:21 AM and 2:56 PM and 3/10/23 at 11:10 AM and 11:11 PM) indicating that there should be 2 tablets remaining and not zero as documented on the controlled drug inventory sheet. There were 2 tablets that were not documented as given to the resident but were noted as removed from the controlled drug inventory. Resident # 57 Hydrocodone (pain) 10 mg/325 mg - 18 tablets were marked as on hand on 2/17/23 on the Controlled Drug Declining Inventory Sheet. Further review of the sheet revealed that one tablet of Hydrocodone was given on 2/17/23, 2/18/23, 2/20/23 at 6:00 AM and 8:00 PM, 2/21/23 and there was a notation that a tablet was wasted, and the count was decreased to 12 however no date is noted, 2/25/23, 2/27/23, 3/3/23, 3/5/23, 3/7/23, 3/11/23, and 3/14/23 - equaling 14 tablets with 5 tablets noted as remaining on 3/14/23. However, review of the MARs for February and March of 2023 revealed the medication was documented twice as being administered to resident #57, (2/17/23 and 2/18/23) indicating that there should be 16 tablets remaining and not 5 as documented on the controlled drug inventory sheet. There were 11 tablets that were not documented as given to the resident but were noted as removed from the controlled drug inventory. Resident # 20 Clonazepam (anxiety) 0.5 mg - 15 tablets were marked as on hand on 1/20/23 on the Controlled Drug Declining Inventory Sheet. Further review of the sheet revealed that one tablet of the Clonazepam was (continued on next page) Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation. LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE TITLE (X6) DATE FORM CMS-2567 (02/99) Previous Versions Obsolete Facility ID: If continuation sheet Page 1 of 2 Event ID: 105975 Printed: 05/28/2026 Form Approved OMB No. 0938-0391 Department of Health & Human Services Centers for Medicare & Medicaid Services STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION (X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: (X2) MULTIPLE CONSTRUCTION 105975 B. Wing A. Building (X3) DATE SURVEY COMPLETED 03/16/2023 NAME OF PROVIDER OR SUPPLIER STREET ADDRESS, CITY, STATE, ZIP CODE Community Health and Rehabilitation Center 3611 Transmitter Road Panama City, FL 32404 For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency. (X4) ID PREFIX TAG SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)